Table 1 Proportion of Pfk13, Pfmdr1 and Pfcrt polymorphisms in day 0, recurrent and recrudescent infections

Pfk13^a

 Samples successfully sequenced

317/323 (98.1%)

88/110 (80.0%)

23/24 (95.8%)

 Wild type (no or mixed mutations detected)

315/317 (99.4%)

87/88 (98.9%)

22/23 (95.7%)

 522C

2/317 (0.6%)

0

0

 578S

6/317 (1.9%)

2/88 (2.3%)

1/23 (4.3%)

Pfmdr1^a

 Samples successfully sequenced

320/323 (99.1%)

95/110 (86.4%)

24/24 (100.0%)

 N86

319/320 (99.7%)

94/95 (98.9%)

23/24 (95.8%)

 86 N/Y

1/320 (0.3%)

0

0

 86Y

0

1/95 (1.1%)

1/24 (4.2%)

 Y184

129/320 (40.3%)

36/95 (37.9%)

8/24 (33.3%)

 184Y/F

79/320 (24.7%)

16/95 (16.8%)

5/24 (20.8%)

 184F

112/320 (35.0%)

43/95 (45.3%)

11/24 (45.8%)

 D1246

290/320 (90.6%)

90/95 (94.7%)

22/24 (91.7%)

 1246D/Y

19/320 (5.9%)

3/95 (3.2%)

2/24 (8.3%)

 1246Y

11/320 (3.4%)

2/95 (2.1%)

0

 NYD

203/320 (63.4%)

50/95 (52.6%)

13/24 (54.2%)

 YFD

1/320 (0.3%)

1/95 (1.1%)

1/24 (4.2%)

 NFD

185/320 (57.8%)

58/95 (61.1%)

15/24 (62.5%)

 NFY

18/320 (5.6%)

2/95 (2.1%)

1/24 (4.2%)

 NYY

21/320 (6.6%)

5/95 (5.3%)

2/24 (8.3%)

 YYD

1/320 (0.3%)

0

0

 YFY

0

0

0

 YYY

0

0

0

Pfcrt^a

 Samples successfully sequenced

318/323 (98.5%)

95/110 (86.4%)

24/24 (100.0%)

 C72

318/318 (100.0%)

95/95 (100.0%)

24/24 (100.0%)

 72S

0

0

0

 M74

314/318 (98.7%)

93/95 (97.9%)

23/24 (95.8%)

 74 M/I

2/318 (0.6%)

0

0

 74I

2/318 (0.6%)

2/95 (2.1%)

1/24 (4.2%)

 N75

312/318 (98.1%)

93/95 (97.9%)

23/24 (95.8%)

 75 N/D

4/318 (1.3%)

0

0

 75E

2/318 (0.6%)

2/95 (2.1%)

1/24 (4.2%)

 K76

312/318 (98.1%)

93/95 (97.9%)

23/24 (95.8%)

 76 K/T

4/318 (1.3%)

0

0

 76T

2/318 (0.6%)

2/95 (2.1%)

1/24 (4.2%)

 CVMNK

316/318 (99.4%)

93/95 (97.9%)

23/24 (95.8%)

 CVIDT^b

2/318 (0.6%)

0

0

 CVMDT^c

2/318 (0.6%)

0

0

 CVIET

2/318 (0.6%)

2/95 (2.1%)

1/24 (4.2%)